“Cautious optimism” is circling once again as the industry approaches 2025. However, many companies are treading water, barely holding on as the market continues at a slow pace. Ali Pashazadeh and Miguel Forte have an open discussion about the state of the market.

Miguel Forte

President International Society for Cell & Gene Therapy; ARM Board Member; CEO and Board Member of Kiji Therapeutics

Ali Pashazadeh

Founder at Treehill Partners